NCT04179643 - AB-1002 in Patients With Class III Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2019

Primary Completion Date

August 20, 2024

Study Completion Date

September 30, 2026

Conditions

Congestive Heart FailureHeart FailureHeart Disease, IschemicCardiovascular DiseasesHeart Failure, SystolicHeart Failure，CongestiveHeart ArrhythmiaHeart Failure, DiastolicHeart; Complications

Interventions

BIOLOGICAL

3 x 10e13vg AB-1002

There are 2 components to AB-1002. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.

Trial Locations (4)

43210

The Ohio State University, Columbus

45219

The Linder Center for Education and Research at The Christ Hospital, Cincinnati

53792

University of Wisconsin at Madison, Madison

55407

Minneapolis Heart Foundation Institute, Minneapolis